Amneal Pharmaceuticals vs Grifols
AMRX and GRFS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMRX and GRFS compare
Amneal Pharmaceuticals grew revenue faster over the last twelve months (8.9% versus 4.3% for Grifols).
Grifols keeps more of each dollar of sales as profit, with a net margin of 5.3% compared with 4.2% at Amneal Pharmaceuticals.
Amneal Pharmaceuticals scores higher on the StockData Score (12 against 9 for Grifols), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMRX | GRFS |
|---|---|---|
| Size and price | ||
| Market cap | $6.9B | – |
| Share price | $21.70 | $8.80 |
| Change, 1 year | 81.6% | 0.80% |
| Change, 5 years | 370% | −25.9% |
| Beta (5Y) | 1.07 | 0.89 |
| Employees | 8,500 | 1,613 |
| StockData Score | ||
| Total score | 12 (better) | 9 |
| Valuation score | 0 | 0 |
| Growth score | 5 (better) | 2 |
| Performance score | 5 (better) | 4 |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 51.7× | – |
| P/S | 2.2× | – |
| P/B | 13.0× | – |
| EV/EBITDA | 20.3× | – |
| P/FCF | 78.6× | – |
| FCF yield | 1.3% | – |
| Fair value | $12.99 | – |
| Margin of safety | −67.1% | – |
| Growth | ||
| Revenue growth (TTM) | 8.9% (better) | 4.3% |
| Revenue growth, 5Y average | 8.7% (better) | 7.1% |
| Net income growth (TTM) | 2159% (better) | 156% |
| EPS growth (TTM) | 2000% (better) | 157% |
| EPS growth, 5Y average | −18.5% | −8.1% (better) |
| Profitability | ||
| Gross margin | 40.2% (better) | 38.0% |
| Operating margin | 15.0% | 16.5% (better) |
| Net margin | 4.2% | 5.3% (better) |
| FCF margin | 2.8% | 10.4% (better) |
| Return on equity | 63.2% (better) | 7.2% |
| Return on invested capital | 16.3% (better) | 14.6% |
| Financial health | ||
| Debt / equity | 5.53 | 0.41 (better) |
| Net debt / EBITDA | 5.81 | 0.79 (better) |
| Interest coverage | – | 2.0× |
| Current ratio | 1.87 | 2.51 (better) |
| Altman Z-score | 1.89 | – |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Payout ratio | – | 31.8% |
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 52.7% | 20.8% |
| Held by insiders | 60.7% | 0.00% |
| Insider net buying, 12 months | −$7.7M | – |
| Short interest, % of float | 9.1% | – |
Go deeper
- AMRX stock overview
- AMRX income statement
- AMRX valuation and score
- GRFS stock overview
- GRFS income statement
- GRFS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.